267 related articles for article (PubMed ID: 28204864)
21. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer.
Shaikh J; Ankola DD; Beniwal V; Singh D; Kumar MN
Eur J Pharm Sci; 2009 Jun; 37(3-4):223-30. PubMed ID: 19491009
[TBL] [Abstract][Full Text] [Related]
22. Anti-inflammatory and apoptotic effects of the polyphenol curcumin on human fibroblast-like synoviocytes.
Kloesch B; Becker T; Dietersdorfer E; Kiener H; Steiner G
Int Immunopharmacol; 2013 Feb; 15(2):400-5. PubMed ID: 23347846
[TBL] [Abstract][Full Text] [Related]
23. Neuroprotective effects of curcumin through autophagy modulation.
Forouzanfar F; Read MI; Barreto GE; Sahebkar A
IUBMB Life; 2020 Apr; 72(4):652-664. PubMed ID: 31804772
[TBL] [Abstract][Full Text] [Related]
24. Curcumin targets in inflammation and cancer.
Deguchi A
Endocr Metab Immune Disord Drug Targets; 2015; 15(2):88-96. PubMed ID: 25772169
[TBL] [Abstract][Full Text] [Related]
25. Curcumin in inflammatory diseases.
Shehzad A; Rehman G; Lee YS
Biofactors; 2013; 39(1):69-77. PubMed ID: 23281076
[TBL] [Abstract][Full Text] [Related]
26. T-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases.
González H; Pacheco R
J Neuroinflammation; 2014 Dec; 11():201. PubMed ID: 25441979
[TBL] [Abstract][Full Text] [Related]
27. Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin.
Ray B; Lahiri DK
Curr Opin Pharmacol; 2009 Aug; 9(4):434-44. PubMed ID: 19656726
[TBL] [Abstract][Full Text] [Related]
28. Curcumin in Alzheimer's disease: Can we think to new strategies and perspectives for this molecule?
Serafini MM; Catanzaro M; Rosini M; Racchi M; Lanni C
Pharmacol Res; 2017 Oct; 124():146-155. PubMed ID: 28811228
[TBL] [Abstract][Full Text] [Related]
29. Potential anti-neuroinflammatory compounds from Australian plants - A review.
Singh A; Raju R; Münch G
Neurochem Int; 2021 Jan; 142():104897. PubMed ID: 33186611
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets.
Aggarwal BB; Sung B
Trends Pharmacol Sci; 2009 Feb; 30(2):85-94. PubMed ID: 19110321
[TBL] [Abstract][Full Text] [Related]
31. Systemic delivery of curcumin: 21st century solutions for an ancient conundrum.
Bisht S; Maitra A
Curr Drug Discov Technol; 2009 Sep; 6(3):192-9. PubMed ID: 19496751
[TBL] [Abstract][Full Text] [Related]
32. Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability.
Onoue S; Takahashi H; Kawabata Y; Seto Y; Hatanaka J; Timmermann B; Yamada S
J Pharm Sci; 2010 Apr; 99(4):1871-81. PubMed ID: 19827133
[TBL] [Abstract][Full Text] [Related]
33. Targeting toll-like receptor 4 to modulate neuroinflammation in central nervous system disorders.
Leitner GR; Wenzel TJ; Marshall N; Gates EJ; Klegeris A
Expert Opin Ther Targets; 2019 Oct; 23(10):865-882. PubMed ID: 31580163
[No Abstract] [Full Text] [Related]
34. Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer.
Gao Y; Li Z; Sun M; Li H; Guo C; Cui J; Li A; Cao F; Xi Y; Lou H; Zhai G
Drug Dev Ind Pharm; 2010 Oct; 36(10):1225-34. PubMed ID: 20545506
[TBL] [Abstract][Full Text] [Related]
35. Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactions.
Adiwidjaja J; McLachlan AJ; Boddy AV
Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):953-972. PubMed ID: 28776444
[TBL] [Abstract][Full Text] [Related]
36. Effects of curcumin on neurological diseases: focus on astrocytes.
Eghbaliferiz S; Farhadi F; Barreto GE; Majeed M; Sahebkar A
Pharmacol Rep; 2020 Aug; 72(4):769-782. PubMed ID: 32458309
[TBL] [Abstract][Full Text] [Related]
37. Curcumin therapeutic promises and bioavailability in colorectal cancer.
Shehzad A; Khan S; Shehzad O; Lee YS
Drugs Today (Barc); 2010 Jul; 46(7):523-32. PubMed ID: 20683505
[TBL] [Abstract][Full Text] [Related]
38. Is curcumin bioavailability a problem in humans: lessons from clinical trials.
Kunnumakkara AB; Harsha C; Banik K; Vikkurthi R; Sailo BL; Bordoloi D; Gupta SC; Aggarwal BB
Expert Opin Drug Metab Toxicol; 2019 Sep; 15(9):705-733. PubMed ID: 31361978
[No Abstract] [Full Text] [Related]
39. Bioavailability of curcumin: problems and promises.
Anand P; Kunnumakkara AB; Newman RA; Aggarwal BB
Mol Pharm; 2007; 4(6):807-18. PubMed ID: 17999464
[TBL] [Abstract][Full Text] [Related]
40. The role of GPCRs in neurodegenerative diseases: avenues for therapeutic intervention.
Huang Y; Todd N; Thathiah A
Curr Opin Pharmacol; 2017 Feb; 32():96-110. PubMed ID: 28288370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
